Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin combined with durvalumab in pre-treated extensive-stage small-cell lung cancer
2022-001114-19Phase 2Terminated
- Sponsor
- Institut Bergonié
- Start
- Apr 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of lurbinectedin and durvalumab in small cell lung cancer (SCLC) (2 arms), sponsored by Institut Bergonié. Primary endpoint: 6-month progression-free rate. Started Apr 2023; status: terminated.
02
Drugs
lurbinectedindurvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2022-001114-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001114-19.